• Home
  • Pegfilgrastim versus filgrastim to accelerate hematopoietic recovery after high-dose melphalan and autologous hematopoietic stem cell transplantation (ASCT) for multiple myeloma.

Pegfilgrastim versus filgrastim to accelerate hematopoietic recovery after high-dose melphalan and autologous hematopoietic stem cell transplantation (ASCT) for multiple myeloma.

Author List
R.L. Olin, S.M. Luger, D.L. Porter, S.J. Schuster, D. Tsai, S. Nasta, A. Perl, A.W. Loren, S. Goldstein, P. Mangan, V. Sherry, K. Cunningham, B. Sachs, K. Hummel, E.A. Stadtmauer
Publication
Biology of Blood and Marrow Transplantation
Publication ID (Profile URL)
https://researcherprofiles.org/profile/79290105
Publication Year
2005
Publication Title
R.L. Olin, S.M. Luger, D.L. Porter, S.J. Schuster, D. Tsai, S. Nasta, A. Perl, A.W. Loren, S. Goldstein, P. Mangan, V. Sherry, K. Cunningham, B. Sachs, K. Hummel, E.A. Stadtmauer. Pegfilgrastim versus filgrastim to accelerate hematopoietic recovery after high-dose melphalan and autologous hematopoietic stem cell transplantation (ASCT) for multiple myeloma. Biology of Blood and Marrow Transplantation. 2005 Feb 1; 11(2):87.